Editorial Commentary: Colistin and a New Paradigm in Drug Development

Clinical Infectious Diseases

Volumn 62, Issue 5, 2016, Pages 559-560

  Van Bambeke, Françoise ^a   Tulkens, Paul M ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

Breakpoints; Colistin; Dosage recommendations; EMA; FDA

Indexed keywords

COLISTIMETHATE; COLISTIN; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; BODY WEIGHT; CREATININE CLEARANCE; DRUG CLEARANCE; DRUG INDUSTRY; HUMAN; NONHUMAN; NOTE; PAENIBACILLUS POLYMYXA; PRACTICE GUIDELINE; PRIORITY JOURNAL; UNITED STATES; DRUG EFFECTS; MICROBIAL SENSITIVITY TEST; MULTIDRUG RESISTANCE;

ANTI-BACTERIAL AGENTS; COLISTIN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS;

EID: 84960155841     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/civ968     Document Type: Note

References (3)

1. Nation RL, Garonzik SM, Li J, et al. Updated US and European dose recommendations for intravenous colistin: how do they perform? Clin Infect Dis 2016; 62:552-8.
2. Kasiakou SK, Michalopoulos A, Soteriades ES, Samonis G, Sermaides GJ, Falagas ME. Combination therapy with intravenous colistin for management of infections due to multidrug-resistant gram-negative bacteria in patients without cystic fibrosis. Antimicrob Agents Chemother 2005; 49: 3136-46.
3. European Medicines Agency. Use of colistin products in animals within the European Union: development of resistance and possible impact on human and animal health. Available at: http://www.ema. europa.eu/docs/en-GB/document-library/Report/2013/07/WC500146813.pdf. Accessed 10 November 2015.